



# 2025 GNIPST BULLETIN (Pharmacy)

Volume-2, Issue- 5



**GURU NANAK INSTITUTE OF PHARMACEUTICAL  
SCIENCE AND TECHNOLOGY**


157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



# Table of Contents

1	Message from Director and Principal	1
2	Recent Researches	2
3	New Drug Approvals	3
4	Clinical Trial News	4
5	Disease Outbreak News	5
6	Campus News	6
7	Book Review Results	7
8	Game Time	8





## MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my warmest greetings to all members of our academic family and well-wishers. This moment offers us a valuable opportunity to reflect on the journey so far and move forward with hope, positivity, and a renewed sense of purpose. At our esteemed institution, we are steadfast in our commitment to fostering a culture of excellence, inclusivity, and innovation.

We continue to dedicate ourselves to nurturing inquisitive minds, encouraging scientific curiosity, and empowering our students to become future leaders in the field of Pharmaceutical Sciences.

Let us move ahead with renewed enthusiasm, unwavering determination, and a shared vision for growth, collaboration, and success.

Wishing you and your loved ones good health, peace, progress, and fulfillment in all your endeavours.

*Prof. (Dr.) Abhijit Sengupta*

## MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and best wishes to all our students, faculty, staff, alumni, and valued partners. May the days ahead bring peace, prosperity, good health, and renewed enthusiasm to your lives.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we remain deeply committed to academic excellence and inclusive development. Since our establishment in 2005,


GNIPST has grown to become a distinguished institution in pharmacy education—recognized by the Pharmacy Council of India (PCI) and honored as the first pharmacy college in the region to receive both NAAC and NBA accreditations. Our 74th position in the National Institutional Ranking Framework (NIRF) 2024 further reflects our unwavering dedication to quality education and professional advancement.

As we continue our academic journey, we reaffirm our mission to nurture intellectual curiosity, promote innovation, and empower students to excel in the dynamic field of pharmaceutical sciences. GNIPST takes pride in offering an environment that supports personal growth, leadership, and a strong commitment to societal well-being.

Let us all move forward with integrity, passion, and a shared sense of purpose. We welcome aspiring pharmacy professionals to join us in shaping a healthier and brighter future.

Wishing you all continued success, fulfillment, and meaningful achievements.

*Prof. (Dr.) Lopamudra Datta*





## RECENT RESEARCHES



WHO issues its first-ever reports on tests and treatments for fungal infections

**MORE INFO**

[www.who.int/](http://www.who.int/)

The World Health Organization (WHO) today published its first-ever reports addressing the critical lack of medicines and diagnostic tools for invasive fungal diseases, showing the urgent need for innovative research and development (R&D) to close these gaps. Fungal diseases are an increasing public health concern, with common infections – such as candida, which causes oral and vaginal thrush – growing increasingly resistant to treatment. These infections disproportionately impact severely ill patients and those with weakened immune systems, including individuals undergoing cancer chemotherapy, living with HIV, and who have had organ transplants.

WHO launches first-ever guidelines on meningitis diagnosis, treatment and care

**MORE INFO**

[www.who.int/](http://www.who.int/)

The World Health Organization (WHO) has today published its first-ever global guidelines for meningitis diagnosis, treatment and care, aiming to speed up detection, ensure timely treatment, and improve long-term care for those affected. By bringing together the latest evidence-based recommendations, the guidelines provide a critical tool for reducing deaths and disability caused by the disease. Despite effective treatments and vaccines against some forms of meningitis, the disease remains a significant global health threat. Bacterial meningitis is the most dangerous form and can become fatal within 24 hours. Many pathogens can cause meningitis with an estimated 2.5 million cases reported globally in 2019. This includes 1.6 million cases of bacterial meningitis which resulted in approximately 240 000 deaths. Around 20% of people who contract bacterial meningitis develop long-term complications, including disabilities that impact quality of life. The disease also carries heavy financial and social costs for individuals, families, and communities.

Increases in vaccine-preventable disease outbreaks threaten years of progress, warn WHO, UNICEF, Gavi

**MORE INFO**

[www.who.int/](http://www.who.int/)

Immunization efforts are under growing threat as misinformation, population growth, humanitarian crises and funding cuts jeopardize progress and leave millions of children, adolescents and adults at risk, warn WHO, UNICEF, and Gavi during World Immunization Week, 24–30 April. Outbreaks of vaccine-preventable diseases such as measles, meningitis and yellow fever are rising globally, and diseases like diphtheria, that have long been held at bay or virtually disappeared in many countries, are at risk of re-emerging. In response, the agencies are calling for urgent and sustained political attention and investment to strengthen immunization programmes and protect significant progress achieved in reducing child mortality over the past 50 years.



FDA

# NEW DRUG APPROVALS

April, 2025

Vanrafia (atrasentan) Tablets

- Company: Novartis Pharmaceuticals Corporation
- Date of Approval: April 2, 2025
- Treatment for: Immunoglobulin A Nephropathy



Jobevne (bevacizumab-nwgd) Injection

- Company: Biocon Biologics Ltd.
- Date of Approval: April 9, 2025
- Treatment for: Colorectal Cancer, Non Small Cell Lung Cancer.



Mezofy (aripiprazole) Oral Film

- Company: CMG Pharmaceutical Co., Ltd.
- Date of Approval: April 15, 2025
- Treatment for: Schizophrenia.



penpulimab-kcqx Injection

- Company: Akeso, Inc.
- Date of Approval: April 23, 2025
- Treatment for: Nasopharyngeal Carcinoma



Zevaskyn (prademagene zamikeracel) Gene-Modified Cellular Sheets

- Company: Abeona Therapeutics Inc.
- Date of Approval: April 28, 2025
- Treatment for: Epidermolysis Bullosa.



Imaavy (nipocalimab-aahu) Injection

- Company: Johnson & Johnson Innovative Medicine
- Date of Approval: April 29, 2025
- Treatment for: Myasthenia Gravis



Atzumi (dihydroergotamine mesylate) Nasal Powder – formerly STS101

- Company: Verastem Oncology
- Date of Approval: May 8, 2025
- Treatment for: Ovarian Cancer



<https://www.drugs.com/newdrugs.html>





# CLINICAL TRIAL NEWS



## 01. Combination Immunotherapy Shrank a Variety of Metastatic Gastrointestinal Cancers

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal cancers, according to results of a clinical trial led by researchers at the National Institutes of Health (NIH). The findings, published April 1, 2025 in Nature Medicine, offer hope that this therapy could be used to treat a variety of solid tumors, which has so far eluded researchers developing cell-based therapies.

## 02. Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease.

Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs.

## 03. Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3K $\alpha$ Inhibitor VVD-159642 for Treatment of Advanced Solid Tumors

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS-driven cancers

## 04. Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis

The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), where there are currently no treatment options approved. These findings further support the differentiated mechanism of oral, brain-penetrant tolebrutinib, targeting disability progression independent of relapse activity.

## 05. Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States

Click Therapeutics, Inc., ("Click") a leader in prescription medical treatments as both prescription digital therapeutics and software-enhanced drug™ therapies, has obtained FDA marketing authorization for the first prescription digital therapeutic for the preventive treatment of episodic migraine. FDA granted the De Novo Classification Request for the company's prescription digital therapeutic, CT-132,

## 06. Orforglipron Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial

Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial. If approved, the company is confident in its ability to launch orforglipron worldwide without supply constraints. This would further Lilly's mission to reduce chronic diseases like type 2 diabetes, which is expected to impact an estimated 760 million adults by 2050.

MORE INFORMATION 

[https://www.drugs.com/clinical\\_trials\\_archive/january-2025.html](https://www.drugs.com/clinical_trials_archive/january-2025.html)



# DISEASE OUTBREAK NEWS (DONS)

April, 2025


## Invasive meningococcal disease - Kingdom of Saudi Arabia

11 April 2025

### Situation at a glance

#### Situation at a glance

On 13 March 2025, the International Health Regulations (IHR) National Focal Point (NFP) for the Kingdom of Saudi Arabia (KSA) reported 11 cases of invasive meningococcal disease (IMD) to WHO. Additionally, between 11 February and 18 March 2025, the WHO Eastern Mediterranean Regional IHR contact point received reports of six isolated cases of IMD, either through notification or bilateral communication with IHR NFPs. These cases involve individuals who had recently returned from Umrah. Meningococcal disease remains a global public health concern, particularly in the context of mass gathering events such as Hajj and Umrah. The government of Saudi Arabia regularly issues health requirements for Hajj and Umrah, including vaccination policies. As of 10 March 2025, KSA health authorities estimated that only 54% of international Umrah pilgrims had complied with the meningococcal vaccination requirements. The significant number of pilgrims traveling to KSA from countries with varying levels of meningococcal disease incidence presents a risk of international spread during these gatherings. Given the recent notification of these cases linked to Umrah, WHO strongly advises all individuals planning to attend mass gatherings such as Hajj and Umrah to receive vaccination against meningococcal disease at least 10 days prior to travel.



**MORE INFO**

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON563>

## Sudan virus disease - Uganda

26 April, 2025

### Situation at a glance

On 26 April 2025, the Ministry of Health (MoH) of Uganda declared the end of the Sudan virus disease (SVD) outbreak after two consecutive incubation periods (a total of 42 days) since the last person confirmed with SVD tested negative for the virus on 14 March 2025. A total of 14 SVD cases (including 12 confirmed cases and two probable cases) including four deaths (two confirmed and two probable) have been reported during this outbreak. WHO and partners provided technical, operational and financial support to the government to contain the outbreak. Although the outbreak has been declared over, health authorities are maintaining surveillance to rapidly identify and respond to any re-emergence. Risk communication and community engagement will also continue to ensure the community stay informed and stigma to those who were affected is minimized.




**MORE INFO**

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON566>



# CAMPUS NEWS



**1. Proud Moment:** Ayan Pal and Debanjan Bhattacharya, B.Pharm 2nd year students of Guru Nanak Institute of Pharmaceutical Science and Technology, secured 1st Position All Over India in the prestigious “FUEL THE FUTURE on MALNUTRITION” competition, organized by Internshala and PepsiCo at Juhu, Mumbai.



**2. Proud Moment:** ★ Congratulations to our brilliant B.Pharm 3rd Year students from GNIPST! ★  
Souvik Chandra (IISc Bengaluru), Sneha Saha (IIT Kanpur), and Nafisha Shafkat (Goa University) have secured the prestigious Science Academies’ Summer Research Fellowship Program 2025 under the esteemed guidance of Prof. Upendra Nongthomba, Prof. Krishnamurthy Muralidhar, and mentors at Goa University. Your achievement makes us proud—wishing you all continued success in your research journey! 🌟📖🌱

**4. News18 Bangla Education Eminence Award 2025:** It was thrilled to announce that Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST) had been awarded by the News18 Bangla Education Eminence Award 2025 in the category of Eminence in Pharmaceutical Science & Research. The award was graciously received by our respected Principal, Prof. (Dr.) Lopamudra Datta, whose visionary leadership inspires us every day.



**Souvik Chandra**  
B. Pharm, 3<sup>rd</sup> Year

Under the Guidance of  
**Prof Upendra Nongthomba**  
IISc Bengaluru



**Sneha Saha**  
B. Pharm, 3<sup>rd</sup> Year

Under the Guidance of  
**Prof. Krishnamurthy Muralidhar**  
IIT Kanpur




**Nafisha Shafkat**  
B. Pharm, 3<sup>rd</sup> Year

Under the Guidance of  
**Prof S. Krishnan**  
Goa University, Goa

MORE INFORMATION  [www.gnipst.ac.in](http://www.gnipst.ac.in)



## BOOK REVIEW COMPETITION RESULTS!




**Aishwarya Bagchi**

Diploma Pharmacy 1st Year



**Abhik Halder**

Diploma Pharmacy 1st year




**Sayan Dutta**


B. Pharm 3rd year



# GNIPST GAME TIME



## CROSS WORD PH-5:



### Across

- 1 Fastest memory
- 4 It is an alloy of Tin and Lead.
- 5 Computer that has been designated to share resources and data
- 6 In a series circuit of resistances, the electrical quantity which remains same
- 8 A form of digital currency, created and held electronically. No one controls it.

### Down

- 2 The searching technique that takes  $O(1)$  time to find data
- 3 In FM, the "F" stands for
- 7 Magnetic Flux has an unit of

*Stay tuned for to the next edition for a shout out to fastest correct answers!*

**Submit your answer**



SCAN  
ME

or

CLICK  
HERE

**Cheers to the Victor!**

Volume -2, Issue -5



**Shaswati Ghosh**  
B.Pharm, 4th Semester

Guru Nanak Institute of Pharmaceutical Science and Technology



## Editor- in- Chief

*Prof. (Dr.) Abhijit Sengupta*

## Managing Editors

Prof. (Dr.) Lopamura Datta

### Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

### Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



## COURSES OFFERED

### PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

### PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

### PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major Recruiters



**Latest news**



[www.gnipst.ac.in](http://www.gnipst.ac.in)



[www.facebook.com](http://www.facebook.com)



[www.instagram.com](http://www.instagram.com)



[www.linkedin.com](http://www.linkedin.com)



[www.youtube.com](http://www.youtube.com)



[api.whatsapp.com](http://api.whatsapp.com)